Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Study Classification
OBSERVATIONAL
Study Start Date
2022-11-30
Study Completion Date
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
An observational study of Cxbladder performance for detection or rule-out of upper tract urothelial cancer. Subjects will be prospectively recruited to a single arm observational study to validate the performance characteristics of Cxbladder for suspected (UTUC) or for patients with a history of UTUC and are under surveillance for recurrence of disease.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Longitudinal Bladder Cancer Study for Tumour Recurrence
NCT05080998
Urothelial Bladder Cancer
RECRUITING
The Cxbladder Monitoring Study
NCT02700659
Urothelial Carcinoma
COMPLETED
The Cxbladder Rule-out of Recurrent Urothelial Carcinoma
NCT03673202
Bladder Cancer
UNKNOWN
Surveillance of High-grade Non-muscle Invasive Bladder Tumours Using the Xpert Bladder Cancer Monitor
NCT04100733
Non-muscle Invasive Bladder Cancer
Urinary Biomarker
ACTIVE_NOT_RECRUITING
NA
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder
NCT02968732
Urothelial Carcinoma
ACTIVE_NOT_RECRUITING
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a single arm observational study prospectively recruiting eligible subjects with no apparent UC of the bladder following white light cystoscopy who have positive or suspicious urine cytology or imaging results.
Participants will undergo all clinical investigations as prescribed by the physician as per standard of care with addition of urine sampling to enable Cxbladder and central urine cytology testing. A mid-stream voided urine sample collected at the time of appointment will be used for Cxbladder and central urine cytology testing. Cxbladder and central cytology results will not be reported to the physician.
Urine sample testing will occur at Pacific Edge Ltd laboratories (Dunedin, New Zealand). Central urine cytology will be processed by an independent testing laboratory (Southern Community Laboratories, Dunedin, New Zealand). The remainder of the urine sample will be used for dipstick analysis of Specific Gravity, Leucocytes, Nitrites, Blood, Haemoglobin, and pH. The unused portion of this sample will be used for local cytology and any other analysis as deemed clinically appropriate. Central urine cytology results are not available to physicians.
Participants will undergo all clinical investigations as prescribed by the physician as per standard of care with addition of urine sampling to enable Cxbladder and central urine cytology testing. A mid-stream voided urine sample collected at the time of appointment will be used for Cxbladder and central urine cytology testing. Cxbladder and central cytology results will not be reported to the physician.
Urine sample testing will occur at Pacific Edge Ltd laboratories (Dunedin, New Zealand). Central urine cytology will be processed by an independent testing laboratory (Southern Community Laboratories, Dunedin, New Zealand). The remainder of the urine sample will be used for dipstick analysis of Specific Gravity, Leucocytes, Nitrites, Blood, Haemoglobin, and pH. The unused portion of this sample will be used for local cytology and any other analysis as deemed clinically appropriate. Central urine cytology results are not available to physicians.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Upper Tract Urinary Carcinoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Suspected to have UTUC following negative cystoscopy but positive or suspicious imaging and/or urine cytology.
2. Under surveillance for UTUC following a previous confirmed diagnosis of UTUC
3. Able to provide a voided urine sample of the required 30 ml minimum volume
4. Able to give written consent
5. Able and willing to comply with study requirement
6. Aged 18 years or older
2. Under surveillance for UTUC following a previous confirmed diagnosis of UTUC
3. Able to provide a voided urine sample of the required 30 ml minimum volume
4. Able to give written consent
5. Able and willing to comply with study requirement
6. Aged 18 years or older
Exclusion Criteria
1. Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection
2. Total cystectomy of the bladder with bowel urinary diversion
3. Pregnancy
2. Total cystectomy of the bladder with bowel urinary diversion
3. Pregnancy
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pacific Edge Limited
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
References
Explore related publications, articles, or registry entries linked to this study.
Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011 Apr;107(7):1059-64. doi: 10.1111/j.1464-410X.2010.09675.x. Epub 2010 Sep 3.
Reference Type
BACKGROUND
Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer. 2009 Jul 1;115(13):2853-62. doi: 10.1002/cncr.24339.
Reference Type
BACKGROUND
Cowan NC. CT urography for hematuria. Nat Rev Urol. 2012 Mar 13;9(4):218-26. doi: 10.1038/nrurol.2012.32.
Reference Type
BACKGROUND
Cowan NC, Turney BW, Taylor NJ, McCarthy CL, Crew JP. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int. 2007 Jun;99(6):1363-70. doi: 10.1111/j.1464-410X.2007.06766.x. Epub 2007 Apr 8.
Reference Type
BACKGROUND
Janisch F, Shariat SF, Baltzer P, Fajkovic H, Kimura S, Iwata T, Korn P, Yang L, Glybochko PV, Rink M, Abufaraj M. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol. 2020 May;38(5):1165-1175. doi: 10.1007/s00345-019-02875-8. Epub 2019 Jul 18.
Reference Type
BACKGROUND
Takahashi N, Glockner JF, Hartman RP, King BF, Leibovich BC, Stanley DW, Fitz-Gibbon PD, Kawashima A. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol. 2010 Apr;183(4):1330-65. doi: 10.1016/j.juro.2009.12.031. Epub 2010 Feb 19.
Reference Type
BACKGROUND
Freudenberg LS, Beyer T. Subjective perception of radiation risk. J Nucl Med. 2011 Dec;52 Suppl 2:29S-35S. doi: 10.2967/jnumed.110.085720.
Reference Type
BACKGROUND
Royal HD. Effects of low level radiation-what's new? Semin Nucl Med. 2008 Sep;38(5):392-402. doi: 10.1053/j.semnuclmed.2008.05.006.
Reference Type
BACKGROUND
Linet MS, Kim KP, Rajaraman P. Children's exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations. Pediatr Radiol. 2009 Feb;39 Suppl 1(Suppl 1):S4-26. doi: 10.1007/s00247-008-1026-3. Epub 2008 Dec 16.
Reference Type
BACKGROUND
Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008 Jul;248(1):254-63. doi: 10.1148/radiol.2481071451.
Reference Type
BACKGROUND
Amis ES Jr, Butler PF, Applegate KE, Birnbaum SB, Brateman LF, Hevezi JM, Mettler FA, Morin RL, Pentecost MJ, Smith GG, Strauss KJ, Zeman RK; American College of Radiology. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol. 2007 May;4(5):272-84. doi: 10.1016/j.jacr.2007.03.002.
Reference Type
BACKGROUND
Messer J, Shariat SF, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int. 2011 Sep;108(5):701-5. doi: 10.1111/j.1464-410X.2010.09899.x. Epub 2011 Feb 14.
Reference Type
BACKGROUND
McHale T, Ohori NP, Cieply KM, Sherer C, Bastacky SI. Comparison of urinary cytology and fluorescence in situ hybridization in the detection of urothelial neoplasia: An analysis of discordant results. Diagn Cytopathol. 2019 Apr;47(4):282-288. doi: 10.1002/dc.24108. Epub 2018 Nov 12.
Reference Type
BACKGROUND
Johannes JR, Nelson E, Bibbo M, Bagley DH. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol. 2010 Sep;184(3):879-82. doi: 10.1016/j.juro.2010.05.023.
Reference Type
BACKGROUND
Kavalieris L, O'Sullivan PJ, Suttie JM, Pownall BK, Gilling PJ, Chemasle C, Darling DG. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. BMC Urol. 2015 Mar 27;15:23. doi: 10.1186/s12894-015-0018-5.
Reference Type
BACKGROUND
O'Sullivan P, Sharples K, Dalphin M, Davidson P, Gilling P, Cambridge L, Harvey J, Toro T, Giles N, Luxmanan C, Alves CF, Yoon HS, Hinder V, Masters J, Kennedy-Smith A, Beaven T, Guilford PJ. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. J Urol. 2012 Sep;188(3):741-7. doi: 10.1016/j.juro.2012.05.003. Epub 2012 Jul 19.
Reference Type
BACKGROUND
Kavalieris L, O'Sullivan P, Frampton C, Guilford P, Darling D, Jacobson E, Suttie J, Raman JD, Shariat SF, Lotan Y. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol. 2017 Jun;197(6):1419-1426. doi: 10.1016/j.juro.2016.12.010. Epub 2016 Dec 14.
Reference Type
BACKGROUND
Lotan Y, O'Sullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, Guilford P, Luxmanan C, Suttie J, Crist H, Scherr D, Asroff S, Goldfischer E, Thill J, Darling D. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urol Oncol. 2017 Aug;35(8):531.e15-531.e22. doi: 10.1016/j.urolonc.2017.03.008. Epub 2017 Mar 31.
Reference Type
BACKGROUND
Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, Kavalieris L, Darling DG. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion(R) FISH, NMP22(R) and cytology based on imputation of multiple datasets. BMC Med Res Methodol. 2015 May 12;15:45. doi: 10.1186/s12874-015-0036-8.
Reference Type
BACKGROUND
Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv. doi: 10.3310/hta14040.
Reference Type
BACKGROUND
Jocham D, Stepp H, Waidelich R. Photodynamic diagnosis in urology: state-of-the-art. Eur Urol. 2008 Jun;53(6):1138-48. doi: 10.1016/j.eururo.2007.11.048. Epub 2007 Dec 10.
Reference Type
BACKGROUND
Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 Aug;76(2):238-243. doi: 10.1016/j.eururo.2019.04.035. Epub 2019 May 16.
Reference Type
BACKGROUND
VandenBussche CJ, Allison DB, Gupta M, Ali SZ, Rosenthal DL. A 20-year and 46,000-specimen journey to Paris reveals the influence of reporting systems and passive peer feedback on pathologist practice patterns. Cancer Cytopathol. 2018 Jun;126(6):381-389. doi: 10.1002/cncy.22006. Epub 2018 May 14.
Reference Type
BACKGROUND
Koya M, Osborne S, Chemasle C, Porten S, Schuckman A, Kennedy-Smith A. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020 Feb 11;20(1):12. doi: 10.1186/s12894-020-0583-0.
Reference Type
BACKGROUND
Davidson PJ, McGeoch G, Shand B. Assessment of a clinical pathway for investigation of haematuria that reduces the need for cystoscopy. N Z Med J. 2020 Dec 18;133(1527):71-82.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pacificedgedx
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT01050504
RECRUITING
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
NCT00872495
RECRUITING
Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC
NCT07225374
RECRUITING
PHASE2
Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder
NCT05077852
UNKNOWN
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301
COMPLETED
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
RECRUITING
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
NCT02647112
COMPLETED
NA
Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma
NCT02326909
COMPLETED
NA
Cystoscopic Imaging Collection and Enhancement pROject
NCT02427321
COMPLETED
Registry for Treatment of Upper Urinary Tract Tumours
NCT02281188
UNKNOWN
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
NCT02351739
COMPLETED
PHASE2
Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy
NCT03345134
NOT_YET_RECRUITING
PHASE2
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy
NCT04018053
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
A Diagnostic for the Early Detection of Bladder Cancer
NCT05347342
ACTIVE_NOT_RECRUITING
Bladder EpiCheck European Haematuria Study
NCT06818136
RECRUITING
Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas
NCT02547350
UNKNOWN
PHASE2
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
NCT03125460
COMPLETED
Identifying Methylation Biomarkers for Monitoring Bladder Tumors
NCT00244205
UNKNOWN
Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer
NCT00350025
COMPLETED
PHASE2
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
NCT02700464
COMPLETED
NA
The Combined Role of FAPI PET and Liquid Biopsy in the Staging and Clinical Management of Bladder Cancer - FUTURE Trial
NCT07257718
NOT_YET_RECRUITING
PHASE2
Bio Clinical Collection of Urothelial Carcinoma
NCT04970472
RECRUITING
Intravesical BCG: is the Urinary Bladder Ready to Receive it
NCT05335512
NOT_YET_RECRUITING